Russell Schuster, III Biography and Net Worth

Chief Commercial Officer of AdaptHealth


Russell Schuster was named Chief Commercial Officer at AdaptHealth in December 2024.

Mr. Schuster joins AdaptHealth from Cardinal Health, where he most recently served as the President for Cardinal Health Canada since November 2020. During his time as President, the business experienced significant organic revenue growth and margin expansion through the implementation and execution of a multi-year strategic plan, refocused commercial strategy and implementation of operating efficiency programs.

Previously, he held the role of Senior Vice President and led the Global Strategy and Business Development efforts for the Medical Segment at Cardinal Health. Mr. Schuster joined Cardinal Health in 2017 as a Vice President, Corporate Development with responsibility for identification and execution of M&A, Partnerships and Joint Ventures across the enterprise. Mr. Schuster has nearly 25 years’ experience in corporate finance, strategy and M&A work and, immediately prior to joining Cardinal Health, he led corporate development efforts for Republic Services in Chicago, IL.

Earlier in his career, Mr. Schuster was a Senior Vice President in investment banking advisory with Barclays (Lehman Brothers). Prior to that, he was with the Transaction Advisory and Corporate Audit groups at Ernst & Young LLP.

Mr. Schuster received his MBA from Northwestern University Kellogg School of Management’s accelerated 1-Year program and his bachelor’s in Accounting/Business Law from Miami University (OH). He is a CPA and previously served on the Board of Directors for MedTech Canada and naviHealth, Inc. until its acquisition by Optum in 2020.

In his free time, Mr. Schuster enjoys spending time with his wife and 2 children, fly-fishing and hiking or traveling.

What is Russell E. Schuster, III's net worth?

The estimated net worth of Russell E. Schuster, III is at least $1.33 million as of June 1st, 2026. Mr. Schuster, III owns 136,538 shares of AdaptHealth stock worth more than $1,328,515 as of June 5th. This net worth evaluation does not reflect any other investments that Mr. Schuster, III may own. Learn More about Russell E. Schuster, III's net worth.

How do I contact Russell E. Schuster, III?

The corporate mailing address for Mr. Schuster, III and other AdaptHealth executives is 220 West Germantown Pike Suite 250, Plymouth Meeting PA, 19462. AdaptHealth can also be reached via phone at (610) 424-4515 and via email at [email protected]. Learn More on Russell E. Schuster, III's contact information.

Has Russell E. Schuster, III been buying or selling shares of AdaptHealth?

Over the course of the past ninety days, Russell E. Schuster, III has sold $113,426.50 of AdaptHealth stock. Most recently, Russell E. Schuster III sold 11,275 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $10.06, for a transaction totalling $113,426.50. Following the completion of the sale, the insider now directly owns 136,538 shares of the company's stock, valued at $1,373,572.28. Learn More on Russell E. Schuster, III's trading history.

Who are AdaptHealth's active insiders?

AdaptHealth's insider roster includes Jason Clemens (CFO), Stephen Griggs (CEO), Solomon III (Director), Ronald Mcdaniel (Director), Frank Mullen (CAO), Albert Prast (Chief Technology Officer), Alan Quasha (Director), Shaw Rietkerk (COO), Russell Schuster, III (Chief Commercial Officer), and Dale Wolf (Director). Learn More on AdaptHealth's active insiders.

Are insiders buying or selling shares of AdaptHealth?

In the last year, AdaptHealth insiders bought shares 5 times. They purchased a total of 2,494,518 shares worth more than $24,352,290.81. In the last year, insiders at the sold shares 3 times. They sold a total of 24,475 shares worth more than $240,362.50. The most recent insider tranaction occured on June, 1st when insider Russell E Schuster III sold 11,275 shares worth more than $113,426.50. Insiders at AdaptHealth own 2.0% of the company. Learn More about insider trades at AdaptHealth.

Information on this page was last updated on 6/1/2026.

Russell E. Schuster, III Insider Trading History at AdaptHealth

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2026Sell11,275$10.06$113,426.50136,538View SEC Filing Icon  
See Full Table

Russell E. Schuster, III Buying and Selling Activity at AdaptHealth

This chart shows Russell E Schuster III's buying and selling at AdaptHealth by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AdaptHealth Company Overview

AdaptHealth logo
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $9.98
Low: $9.76
High: $10.07

50 Day Range

MA: $11.53
Low: $9.65
High: $13.38

2 Week Range

Now: $9.98
Low: $8.06
High: $13.43

Volume

140,764 shs

Average Volume

1,329,483 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47